NASDAQ: NNNNAnbio Biotechnology Stock
$6.43+0.00 (+0%)
Updated Apr 29, 2025
NNNN Price
$6.43
Fair Value Price
N/A
Market Cap
$914.93M
52 Week Low
$5.18
52 Week High
$7.82
P/E
114.82x
P/B
53.22x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$8.19M
Earnings
$2.37M
Gross Margin
71.9%
Operating Margin
28.99%
Profit Margin
29%
Debt to Equity
0.1
Operating Cash Flow
$2M
Beta
-0.04
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NNNN Overview
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NNNN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NNNN
Ranked#137 of 462
Ranked#137 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important NNNN news, forecast changes, insider trades & much more!
NNNN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NNNN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NNNN was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NNNN is poor value based on its earnings relative to its share price (114.82x), compared to the US market average (29.19x)
P/E vs Market Valuation
NNNN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more NNNN due diligence checks available for Premium users.
Valuation
NNNN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
114.82x
Industry
-158.75x
Market
29.19x
NNNN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NNNN is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
NNNN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
53.22x
Industry
4.37x
NNNN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NNNN's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
NNNN's Earnings (EBIT) of $2.37M... subscribe to Premium to read more.
Interest Coverage Financials
NNNN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$18.9M
Liabilities
$1.7M
Debt to equity
0.1
NNNN's short-term assets ($18.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NNNN's short-term assets ($18.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NNNN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
NNNN's operating cash flow ($2.08M)... subscribe to Premium to read more.
Debt Coverage Financials
NNNN vs Biotech Stocks
Anbio Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.